Last reviewed · How we verify
T-cell acute lymphoblastic leukemia
Approved treatments
- Arranon · Novartis
Arranon works by inhibiting the enzyme responsible for converting nucleosides into their active forms, thereby preventing DNA synthesis in cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- T-cell acute lymphoblastic leukemia patent landscape — cliff calendar, originator estates, attackable patents
- T-cell acute lymphoblastic leukemia treatment landscape brief
- T-cell acute lymphoblastic leukemia treatment updates RSS
Frequently asked questions about T-cell acute lymphoblastic leukemia
What drugs treat T-cell acute lymphoblastic leukemia?
Tracked treatments include Arranon.
What is the treatment for T-cell acute lymphoblastic leukemia?
Standard treatment for T-cell acute lymphoblastic leukemia includes Arranon. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: T-cell acute lymphoblastic leukemia patent cliff · T-cell acute lymphoblastic leukemia CI report
- Treatment: Arranon · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing